Novartis reports two patient deaths after treatment with Zolgensma - Endpoints News

Two children with spinal muscular atrophy have died after receiving Novartis’ Zolgensma, a gene therapy designed as a one-time treatment for the rare fatal disease. The deaths, which resulted from acute liver failure, occurred in Russia and Kazakhstan, Novart…

Zantac became one of the most well-known drugs on the market after being FDA-approved in 1983 — and now close to four decades later, lawsuits over safety concerns are rattling analysts and investors.… [+514 chars]

full article...